1. Introduction {#sec1}
===============

The type-I interferon (IFN) response provides a robust innate immune defence against pathogens, instigated by the detection of pathogen-associated molecular patterns (PAMPs) such as foreign nucleic acid and bacterial lipopolysaccharide (LPS) ([@bib45]). PAMPs are detected by intracellular sensor proteins called pathogen recognition receptors (PRRs), including toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), amongst others ([@bib45]). PRR-induced signalling pathways result in the activation of the latent transcription factors IFN regulatory factor 3 (IRF3), IRF7 (following prolonged stimulation), and nuclear factor kappa-light-chain-enhancer of activated B-cells (NFκB), which initiate the transcription of type-I IFNs (IFNα and IFNβ) and the proinflammatory cytokines interleukin (IL)-6 and tumor necrosis factor-α (TNFα) ([@bib45]). These secreted factors act in an autocrine and paracrine manner to induce expression of antimicrobial proteins as well as activate and recruit immune cells, promoting pathogen clearance ([@bib45]). Due to the profound effects of these signalling proteins on cell biology, the type-I IFN response is tightly regulated by numerous mechanisms to prevent aberrant signalling that can promote many disease states, including inflammation, autoimmunity and cancer ([@bib13]; [@bib19]; [@bib47]; [@bib62]; [@bib70]).

We recently characterised a novel inhibitor of the type-I IFN response, C6orf106, which promotes the degradation of the transcriptional coactivators p300 and cAMP-response element-binding protein-binding protein (CBP) within the nucleus and inhibits IRF3-DNA binding, resulting in significantly impaired transcription of type-I IFNs and TNFα, but not IL-6 ([@bib3]). Based on our data, and those of others ([@bib8]), this protein was renamed **[I]{.ul}**nflammation and **[L]{.ul}**ipid **[R]{.ul}**egulator with **[U]{.ul}**BA-like and **[N]{.ul}**BR1-like domains (ILRUN). Genome-wide analyses have also identified the *ILRUN* gene as a body mass index (BMI)-associated locus and positive correlations between ILRUN expression and the malignancy and invasiveness of several cancers have been identified ([@bib5]; [@bib28]; [@bib39]; [@bib61]; [@bib99]). The latter studies postulate that ILRUN promotes the extracellular signal-related kinases (ERK) signalling pathway, reducing expression of the cell adhesins E-cadherin and p120ctn, thereby promoting metastasis ([@bib39]; [@bib99]). This suggests that ILRUN may be of importance to several diseases of significant concern to human health and, therefore, an attractive therapeutic target. At present, however, there is limited information on the molecular and structural biology of ILRUN.

In this report, we characterise ILRUN using bioinformatic, expression analysis and experimental approaches. We show that the N-terminal ubiquitin-associated (UBA)-like and central neighbour of BRCA1 gene 1 (NBR1)-like domains are evolutionarily well-conserved in animals, and both these domains contribute to ILRUN-mediated inhibition IRF3 signalling; the C-terminal disordered region, whose sequence is much more disparate, appears dispensable for this function. We also present a crystal structure of the NBR1-like domain and a structure prediction of the UBA-like domain, in addition to performing expression analysis from published datasets to elucidate ILRUN expression in different human tissues and immune cell types, identifying ILRUN as appearing to be most abundant in testis and activated B-cells. Together, these data advance our knowledge of ILRUN biology and its roles in human health and disease.

2. Materials and methods {#sec2}
========================

2.1. Cells {#sec2.1}
----------

HeLa cells (ATCC CCL-2) were maintained in Eagle\'s minimum essential medium (EMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 10 mM HEPES, 2 mM L-glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin (Thermo Fisher Scientific). All cells were kept at 37 °C in a humidified incubator (5% CO~2~).

2.2. ILRUN mutant plasmid generation {#sec2.2}
------------------------------------

The ΔUBA and Δdisordered (Δdis) coding sequences were amplified from the pre-existing pCAGGS-ILRUN-FLAG vector (expressing C-terminally FLAG-tagged human ILRUN), previously described in ([@bib3]), using forward and reverse primers as in Supplementary Table A1. The ΔNBR1 coding sequence was designed upon the naturally occurring isoform ILRUNb (NCBI NP_073595.2) and was synthesised by GenScript with a C-terminal FLAG coding sequence. All amplicons were ligated into the mammalian expression vector pCAGGS using the *SacI* and *XhoI* restriction sites and transformed into chemically competent *Escherichia coli* (MAX Efficiency DH5α competent cells, Thermo Fisher Scientific, Massachusetts, United States). Following Sanger sequencing to confirm correct sequences, plasmids were propagated in DH5α *E.coli* and purified using a Qiagen (Hilden, Germany) EndoFree Plasmid Maxi kit as specified by the manufacturers.

2.3. DNA transfection and poly(I:C) stimulation {#sec2.3}
-----------------------------------------------

HeLa cells in 24-well plates were reverse transfected with 300 ng of endotoxin free plasmid DNA and 1 μL Lipofectamine 2000 in OptiMEM (Thermo Fisher Scientific) as previously described. Cells were stimulated with 5 μg/mL high molecular weight poly(I:C) (Invivogen, California, United States) by transfection (1.5 μL Lipofectamine 2000) for 6 h.

2.4. RNA purification, reverse transcription, and quantitative real-time PCR {#sec2.4}
----------------------------------------------------------------------------

HeLa cells were lysed in TRIzol (Thermo Fisher Scientific), and RNA was extracted according to the manufacturer\'s protocols. Following DNase treatment (RQ1 DNase, Promega, Wisconsin, United States), 500 ng of RNA was reverse-transcribed to DNA using SensiFast reverse transcriptase (Bioline, London, United Kingdom) first-strand cDNA synthesis protocols. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed using SYBR Green (Applied Biosystems, California, United States) on a StepOne Plus PCR cycler (Applied Biosystems). PCR cycling for gene detection was at 95 °C for 10 min followed by 45 cycles of 95 °C for 15 sec and 60 °C for 1 min. A melting curve analysis was performed to eliminate primer--dimer artefacts and to verify the specificity of the assay. Cytokine expression was assayed using the ΔΔCT method and normalized to GAPDH. Primers used in qRT-PCR analyses are as previously described ([@bib3]).

2.5. IRF3 DNA binding assays and IFN-β ELISA {#sec2.5}
--------------------------------------------

HeLa cells were reverse-transfected in 6 cm dishes (as described above but scaled up according to dish size) for 18 h then stimulated with transfected poly(I:C) for 6 h. Cells were incubated on ice in hypotonic buffer (20 mM HEPES, 5 mm NaF, 10 μM Na~2~MoO~4~, 0.1 mM EDTA) for 15 min followed by cytoplasmic membrane disruption with 0.1% Nonidet P-40. Nuclei were pelleted at 12,000 × *g* for 30 sec, washed in hypotonic buffer, and lysed in complete lysis buffer on ice for 45 min (supplemented with phosphatase and protease inhibitors and DTT, Abcam, Cambridge, United Kingdom). Debris was removed by centrifugation and nuclear protein extracts were quantified using a bicinchoninic acid assay (Pierce, Massachusetts, United States). 10 μg of nuclear protein (in duplicate) was applied to an IRF3 transcription factor assay plate (ab207210, Abcam) and DNA binding was assayed as indicated by the manufacturer. Supernatants collected from transfected cells were assayed for IFN-β secretion using a sandwich ELISA kit ([elisakit.com](http://elisakit.com){#intref0010}, Victoria, Australia) according to the manufacturer\'s protocols. IFN-β concentrations were calculated by comparison with standards using a polynomial regression method.

2.6. Crystallisation of ILRUN NBR1 domain {#sec2.6}
-----------------------------------------

The full-length ILRUN gene was synthesised with codon-optimisation for *E. coli* expression and sub-cloned into pET43 with a C-terminal His~6~-tag. The construct was transformed into BL21 (DE3) cells and grown in Terrific Broth with 100 μg/mL carbenicillin (GoldBio, Missouri, United States) at 37 °C to an OD~600~ = 1.1. Expression was induced with 1 mM isopropyl-β-D-thiogalactopyranoside (GoldBio) and left for 3 h before harvesting at 5000 × *g* for 10 min. For a wet pellet weight of 25 g, 100 mL of lysis buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 2 mM MgCl2, 10 mM imidazole. The lysis buffer was supplemented with \~20 U/mL of Benzonase Nuclease (MerckMillipore) and 2 cOmplete EDTA-free protease inhibitor tablets (Roche, Basel, Switzerland) before lysing with three passes through an EmulsiFlex C-5 (Avestin, Ontario, Canada) at 15,000 psi. The lysate was cleared by centrifugation at 48,000 g. The supernatant was loaded onto an ÄKTAexpress (along with all columns, GE Lifesciences, Illinois, United States) with the following three step program: 1) 1 mL HisTrap crude washed with 20 column volumes of wash buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 20 mM imidazole) and eluted with 5 column volumes of elution buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 250 mM imidazole). The following two steps use buffer A (20 mM Tris-HCl, pH 8.0) and B (20 mM Tris-HCl, pH 8.0, 1000 mM NaCl). 2) The eluate was automatically loaded onto a HiPrep 16/10 Desalt run in 5% B. 3) and the protein peak was collected to inject into a 1 mL HiTrap Q HP column. After a 20 column volume wash at 5% B, the protein was eluted in a 5--50%B gradient over 20 column volumes. The ILRUN-containing peak was finally polished and assessed for homogeneity on a Superdex 75 16/600 column in 20 mM Tris-HCl, 8.0, 150 mM NaCl. Typically, the final yield was between 0.5 and 1.0 mg/L of culture.

Small crystals were readily obtained from many conditions in sparse matrix vapour diffusion experiments with *in situ* chymotrypsin treatment. To obtain larger, single crystals, a small quantity of the full-length ILRUN was treated with chymotrypsin (Sigma Aldrich, Missouri, United States) in a 30:1 (w:w) ILRUN:chymotrypsin ratio for 1 h at room temperature. The proteolysis was stopped with addition of 1 mM PMSF and the NBR1 domain isolated by gel filtration as above. The appropriate fractions were concentrated in an Amicon Ultra-4 3 kDa MWCO ultrafiltration device (MerckMillipore, Massachusetts, United States) to A~280~ = 3.0. Single crystals were obtained by mixing 150 nL with 30 nL of seeds made from small crystals mentioned above and 120 nL of 1 M ammonium sulfate and 0.15 M trisodium citrate-citric acid, pH 5.5. Drops containing thin single plates had an equal volume of 3 M sodium malonate, pH 5.5, added, before being harvested and flash cooled in liquid nitrogen.

Diffraction experiments were measured at the MX2 beamline at the Australian Synchrotron (Clayton, Australia) at a wavelength of 1.45865 Å. Images were processed using autoPROC ([@bib80]; [@bib86]) which indexed and integrated with XDS ([@bib29]) and then scaled and merged with Pointless, Aimless and Truncate from the CCP4 suite ([@bib92]). Automated molecular replacement was carried out with MrBUMP with the most favourable solution that was used for model building being chain A of the PDB entry 4OLE. The model was iteratively built with cycles of Coot and autoBUSTER using local secondary structure restraints ([@bib10]; [@bib69]). The model was validated with Molprobity ([@bib91]).

2.7. Transcript expression data mining {#sec2.7}
--------------------------------------

The mined transcript expression data analysed and compiled by the May\'ayan Lab, Mount Sinai Center for Bioinformatics was downloaded from their ARChS4 website ([amp.pharm.mssm.edu/archs4/download.html]{.ul}) ([@bib34]). Published RNA-seq datasets were selected based on the following criteria: i) contained \>3 healthy control replicates, ii) were \>1000 MBases in size and iii) were derived from a tissue or immune cell type of interest. Metadata associated with each sequence read archive was downloaded from the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/){#intref0015}) and R scripts were written to extract associated *ILRUN* isoform expression levels.

2.8. Statistics {#sec2.8}
---------------

The difference between multiple groups was analysed by one- or two-way ANOVA with Bonferroni post-test. A *P* value of \<0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Description of ILRUN genomic organisation of ILRUN locus {#sec3.1}
-------------------------------------------------------------

The human *ILRUN* gene ([Figure 1](#fig1){ref-type="fig"}A) is located on chromosome 6 (locus p21.31) and flanked by genes encoding SAM pointed domain-containing ETS transcription factor (SPDEF) and small nuclear ribonucleoprotein polypeptide C (SNRPC). SPDEF is a transcription factor expressed in prostate, trachea and colon epithelium that is involved in differentiation and overexpressed in prostate and breast cancers, while SNRPC is a component of the U1 small nuclear ribonucleoprotein splicosome that functions pre-mRNA processing ([@bib67]; [@bib71]). The gene contains six exons that produce three transcript variants, ILRUNa, ILRUNb and ILRUNc (also referred to as ILRUN-202, ILRUN-203 and ILRUN-201, respectively; [Figure 1](#fig1){ref-type="fig"}B & C). ILRUNa and ILRUNb encode for proteins of the same name, ILRUNa (which we will refer to as simply ILRUN) is the full-length protein while ILRUNb is shorter due to loss of exon 4 in the transcript. ILRUNa and ILRUNb both lack the non-protein encoding exon 2 and exon 1 is additionally truncated at the 5′ end of ILRUNa, resulting in a shorter 5′ UTR compared to ILRUNb. ILRUNc lacks exon 1 and the majority of the 3′ UTR encoded by exon 6, but contains exon 2, resulting in a distinct 5' UTR to ILRUNa and ILRUNb.Figure 1Genomic organisation of the human ILRUN locus. (A) Schematic of the human *ILRUN* gene mapped to chromosome 6; chromosome image was obtained from the Genome Decoration Page (NCBI). Arrows denote the direction of genes transcription. (B) Intron-exon organisation of the human *ILRUN* gene. (C) Three transcripts are expressed from the *ILRUN* gene; ILRUNa lack exon 2 and exon 1 is 5′ terminally truncated, ILRUNb lacks exon 2 and 5 and ILRUNc lacks exon 1 and the majority of exon 6. Protein coding sequences (CDS; red) and untranslated regions (UTR; white) for each transcript are shown.Figure 1

3.2. ILRUN is widely expressed and appears most abundant in testis and activated B-cells {#sec3.2}
----------------------------------------------------------------------------------------

To gain further insights into the biological functions of ILRUN we performed expression analysis from publicly-available published transcriptomics data ([@bib9]; [@bib15]; [@bib16]; [@bib25]; [@bib27]; [@bib32]; [@bib35]; [@bib49]; [@bib50]; [@bib55]; [@bib58]; [@bib63]; [@bib65]; [@bib79]; [@bib82]; [@bib83]; [@bib85]; [@bib90]; [@bib98]) to investigate the apparent expression of ILRUN transcripts in different human tissues ([Figure 2](#fig2){ref-type="fig"}A). ILRUNa transcripts could be detected in all tissues examined, though only very low expression could be detected in spleen and pancreas. Highest abundance was detected in the testis, followed by heart, ovary and adipose. ILRUNb transcripts followed a similar pattern to that of ILRUNa, but were globally much less abundant, with the highest expression detected in the heart and adipose. ILRUNc transcript expression was very low in most tissues, apart from testis and ovary.Figure 2Human ILRUN appears most highly expressed in the testis and activated B-cells. Scatter plots showing expression of *ILRUN* gene transcripts ILRUNa, ILRUNb and ILRUNc in human tissues (A) and immune cells (B). Lines denote the mean (±SEM). ILRUN expression levels were obtained from peer-reviewed, publicly-available transcriptomics datasets ([@bib9]; [@bib15]; [@bib16]; [@bib25]; [@bib27]; [@bib32]; [@bib35]; [@bib49]; [@bib50]; [@bib55]; [@bib58]; [@bib63]; [@bib65]; [@bib79]; [@bib82]; [@bib83]; [@bib85]; [@bib90]; [@bib98]).Figure 2

Due to the immunological functions of ILRUN ([@bib3]), we also investigated its expression in different immune cell populations ([Figure 2](#fig2){ref-type="fig"}B). Highest expression of ILRUNa transcripts appeared to be in activated B-cells, followed by CD4+ T-cells and dendritic cells. ILRUNb was again expressed at much lower level than ILRUNa and was most prominent in macrophages. ILRUNc was poorly expressed in the cell types examined, except for activated B-cells.

3.3. ILRUN is a well-conserved protein that contains UBA-like and NBR1-like domains and a disordered region {#sec3.3}
-----------------------------------------------------------------------------------------------------------

ILRUN (accession no. [NP_077270.1](ncbi-p:NP_077270.1){#intref0020}) is a 298 amino acid protein in humans that is posited to possess a N-terminal UBA-like domain (residues 23--64) and a central NBR1-like domain (residues 71--180; [Figure 3](#fig3){ref-type="fig"}A), also referred to as an FW domain due to its four conserved tryptophan residues ([@bib1]). The C-terminal region (residues 181--298) is predicted to be largely unstructured ([@bib1]), which we have termed the disordered region, and contains three phosphorylation sites at serine residues 215, 222 and 272; these were identified by phosphoproteomic studies ([@bib43]; [@bib53]; [@bib60]; [@bib101]). The shorter ILRUNb isoform (accession no. [NP_073595.2](ncbi-p:NP_073595.2){#intref0025}) is 232 amino acids, lacking residues 105--170 (Δ105 -- 170) of the NBR1 domain.Figure 3ILRUN is a well-conserved protein that contains UBA-like and NBR1-like domains and a disordered region. (A) Predicted protein domain architecture of human ILRUN and ILRUNb. Numbers represent amino acid positions in full-length ILRUN. Putative phosphorylation sites are denoted by an encircled P. (B) Phylogenetic analysis of ILRUN genes in different species. A rooted tree was constructed from the amino acid sequences of ILRUN using an unweighted pair group method with arithmetic mean using Geneious Prime 2018 version 11.1.4 (Biomatters Ltd.). Numbers indicate number of substitutions per 100 amino acids from a common ancestor. GenBank accession numbers for the respective genes are shown in Supplementary Table A2. (C) Percent amino acid similarity for each domain of ILRUN shown in (A), and for full-length protein, from the species listed in (B).Figure 3

ILRUN orthologues have been identified in nearly all metazoans, with sequence deviation on par with evolutionary divergence ([@bib33]). This is reflected in phylogenetic analysis of ILRUN sequences from representative species of different chordate classes, showing stepwise divergence from a common ancestor consistent with their evolutionary distance to humans ([Figure 3](#fig3){ref-type="fig"}B). Indeed, ILRUN is strongly conserved within this phylum, as amphibian (*Xenopus tropicalis*) ILRUN retains 83.6% total protein similarity to that of humans ([Figure 3](#fig3){ref-type="fig"}C). ILRUN of fish (*Danio rerio*), birds (*Taeniopygia guttata*) and other mammals (*Mus musculus*) show even greater similarity: 87.0%, 93.3% and 96.6%, respectively. Most differences are localised to the disordered domain, which shows a much stronger decline in sequence similarity (91.5% in mice, 88.1% in birds, 73.9% in fish and 52.5% in amphibians) to that of the total protein. This is also associated with a reduction in region length (111 amino acids in mice and birds, 103 in fish and 98 in amphibians, compared to 118 in humans). The UBA-like and NBR1-like domains, on the other hand, are very well-conserved, with a minimum similarity of 97.1% (birds) and 93.6% (fish), respectively.

ILRUN of other phyla appears to be much more diverse, with all domains/regions of nematode ILRUN (*Caenorhabditis elegans*) substantially different to that of humans, 65.1% for the UBA-like domain, 52.5% for the NBR1-like domain and 28.6% for the disordered region. In addition to significant shortening of the disordered domain (52 residues), the size of the NBR1-like domain of nematode ILRUN is also reduced (89 residues compared to 110 in chordates). Despite this divergence, three of the four conserved tryptophan residues of the NBR1-like domain are retained in nematodes, with the forth substituted to a structurally similar phenylalanine residue ([Figure 4](#fig4){ref-type="fig"}). Of the three phosphorylation sites identified for ILRUN, S~215~ is the best conserved, present in all chordates but not nematodes, while S~222~ is only present in mammals and S~272~ in mammals and birds ([Figure 4](#fig4){ref-type="fig"}).Figure 4Multiple alignment of human ILRUN with orthologues from other species. Multiple sequence alignments of ILRUN proteins from different species were performed using Clustal Omega (European Bioinformatics Institute). Identical (∗), conserved (:) and semi-conserved (.) residues are denoted below the sequences. Arrows indicate key tryptophan (W) residues of the NBR1 domain and putative phosphorylation sites are denoted by an encircled P.Figure 4

### 3.3.1. Crystal structure of the NBR1-like domain and predicted structures of the UBA-like domain of ILRUN {#sec3.3.1}

In order to gain insights into the potential function of the domains/regions of ILRUN, we solved the crystal structure of the NBR1-like domain of ILRUN and used QUARK *ab initio* structure prediction software ([@bib95], [@bib94]) to predict the structure of the UBA-like domain ([Figure 5](#fig5){ref-type="fig"}). UBA-like domains are largely involved in binding to ubiquitin and ubiquitin-like (UBL) proteins, which function as post-translational modifiers that target proteins to specific cellular pathways or modify their function ([@bib64]). Ubiquitin is 76 amino acid globular protein that is commonly regarded as a marker of proteosomal degradation via conjugation to lysine residues in a target protein by E3 ubiquitin ligases, in association with E1 ubiquitin-activating and E2 ubiquitin-transferring enzymes ([@bib64]). As ILRUN promotes the degradation of CBP/p300 ([@bib3]), it would seem likely that its UBA-like domain interacts with ubiquitinated CBP/p300 and target them to the proteosome. Prototypical UBA-like domains are three-helix bundles containing a conserved MGF loop between helices 1 and 2 (α1 and α2) which is a hydrophobic binding motif that mediates ubiquitin binding ([@bib48]). Structure prediction suggests that the residues corresponding to the UBA-like domain of ILRUN (residues 23--64) form this bundle ([Figure 5](#fig5){ref-type="fig"}A, shown in red); this was confirmed using PDBeFold (EMBL-EBI) structure comparison software, which returned similarity with existing UBA-like domains (top 10 hits are listed in Supplementary Table A3). Notably, the UBA-like domain of ILRUN contained an LGF motif, though the substitution of leucine for methionine in this motif may not be expected to impact ubiquitin binding as this is also found in the ubiquitin-binding UBA2 domain of the DNA repair protein hHR23A ([@bib87]). In addition, upstream residues of the UBA-like domain may form an additional helix at the N-terminus (α0) near the UBA-like domain, perhaps forming a non-canonical four-helix UBA-like domain, which has been observed previously in human nuclear RNA export factor (NXF) 1/2 and yeast tyrosyl DNA phosphodiesterase 2 (TDP2) ([@bib23]; [@bib59]).Figure 5Modelling of UBA-like domain and structural determination of NBR1-like domain of ILRUN. (A) Ribbon diagram of a structure prediction of residues 1--70 of ILRUN, including the predicted UBA-like domain (residues 23--64, shown in red), using QUARK *ab initio* structure prediction software ([@bib95], [@bib94]). Secondary structure and predicted ubiquitin-binding (LGF) motif are indicated. (B) Ribbon diagram of a 2.5 Å crystal structure of the ILRUN NBR1-like domain obtained by limited proteolysis. Secondary structure and conserved tryptophan (W) residues are indicated, and sequences not present in ILRUNb (residues 105--170) are shown in green. (C) 2D schematic of the ribbon diagram shown in (B). Graphics in (A) and (B) were generated using UCSF Chimera ([@bib57]).Figure 5

The central domain of ILRUN is termed NBR1-like due to its homology to the FW domain of NBR1 ([@bib1]). At present only NBR1 and ILRUN have been categorised to possess a FW/NBR1-like domain in animals, but it has been identified in several bacterial proteins ([@bib1]). Our 2.5 Å crystal structure of the ILRUN NBR1-like domain obtained by limited proteolysis consists of seven antiparallel β-strands arranged in a small β-sandwich ([Figure 5](#fig5){ref-type="fig"}B; deposited in the RCSB Protein Data Bank under ID 6VHI; statistics shown in Supplementary Table A4). It adopts a fibronectin type-III topology ([Figure 5](#fig5){ref-type="fig"}C) and the location of these β-sheets are similar to previous secondary structure predictions of the FW domains of ILRUN and NBR1 from several different species, which proposed a six β-sheet domain, lacking β4 ([@bib1]). Three of the four conserved tryptophans (W~99~, W~109~ and W~159~) are buried in the hydrophobic core of the domain whereas the fourth (W~174~) is solvent exposed ([Figure 5](#fig5){ref-type="fig"}B).

3.4. Both the UBA-like and NBR1-like domains of ILRUN are necessary for inhibition of IRF3-dependent DNA-binding and induction of IFNβ gene expression, while the disordered region appears dispensable {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To evaluate the contributions of each of the domains of ILRUN to its function in inhibiting IRF3-dependent IFNβ gene expression, we generated three mutant constructs containing deletions of each domain ([Figure 6](#fig6){ref-type="fig"}A). ΔUBA contains deletion of residues 1--74, removing the UBA-like domain and all residues upstream of the NBR1-like domain, corresponding to the predicted protein sequence encoded by ILRUNc. ΔNBR1 is homologous in sequence to ILRUNb, lacking residues 105--170 of the NBR1-like domain. Finally, we truncated the disordered domain at residue 193 (Δdis) to not impact a hydrophobic patch that may constitute a possible transmembrane domain (not shown).Figure 6Both the UBA-like and NBR1-like domains of ILRUN are necessary for inhibition of IRF3 signalling, while the disordered region is dispensable. (A) Schematic of ILRUN mutants, including wild-type ILRUN, ΔUBA, lacking residues 1--75, ΔNBR1, lacking residues 105--170, and Δdis, lacking residues 194--298. (B) HeLa cells were transfected with plasmids expressing the indicated proteins (or empty vector/pCAGGS) for 24 h before treatment with transfected poly(I:C) (5 μg/mL) for 6 h, with cells collected and analyzed for mRNA expression of the listed cytokines by qRT-PCR. (C) HeLa cells were transfected with plasmids expressing the indicated proteins and stimulated with poly(I:C), and the nuclear proteins were extracted using a hypotonic lysis method. Nuclear proteins (10 μg) were analyzed for IRF3--DNA binding. (D) Cell supernatants from cells used in (C) were analysed for IFN-b protein by ELISA assay. Error bars denote ±SEM of three independent experiments, and asterisks show significant changes compared with controls as measured by one- or two-way ANOVA with Bonferroni post-test (∗∗∗, *p* \< 0.001; ∗∗, *p* \< 0.01).Figure 6

These mutant constructs, in addition to full-length ILRUN and a negative control expressing GFP or empty vector (pCAGGS), were transfected into HeLa cells, stimulated with poly(I:C) (5 μg/mL, 6 h), and IRF3-DNA binding assessed using an IRF3 transcription factor kit (abcam; [Figure 6](#fig6){ref-type="fig"}C), IFNβ mRNA and protein expression were also quantified by qRT-PCR ([Figure 6](#fig6){ref-type="fig"}B) and ELISA ([Figure 6](#fig6){ref-type="fig"}D), respectively. Overexpression of wild-type ILRUN inhibited IRF3 signalling, as expected ([@bib3]), marked by a reduction in IRF3-DNA binding ([Figure 6](#fig6){ref-type="fig"}B), IFNβ secretion ([Figure 6](#fig6){ref-type="fig"}D) and transcription of IFNα, IFNβ and TNFα transcription ([Figure 6](#fig6){ref-type="fig"}C) compared to controls. The deletion of either the UBA-like (ΔUBA) or NBR1-like (ΔNBR1) domains abrogated the functional activity of ILRUN across all assays employed, indicating both these domains are necessary to inhibit IRF3 signalling. Deletion of the disordered domain (Δdis) did not appear to have an impact on ILRUN function in these assays.

4. Discussion {#sec4}
=============

The type I IFNs are critical regulators of the antiviral immune response, inducing an antiviral state via production of interferon-stimulated genes (ISGs), upregulating major histocompatibility complex expression to promote lysis of infected cells, and triggering further cytokine and chemokine expression to recruit immune cells to fight infection ([@bib74]). Type I IFNs also promote differentiation and maturation of dendritic and natural killer cells and perform both positive and negative regulatory roles in adaptive immune responses to infection ([@bib18]; [@bib45]; [@bib75]). Through the sharing or redundancy of signalling pathways, type-I IFN production is often accompanied by the production of pro-inflammatory cytokines, including IL-6 and TNFα, which stimulate acute phase responses, hematopoiesis, and further immune activation ([@bib78]). Whilst these cytokines are essential for antimicrobial defence, aberrant regulation of their synthesis results in autoimmune diseases including rheumatoid arthritis, lupus and systemic sclerosis ([@bib74]). Excessive proinflammatory responses can also lead to fatal 'cytokine storm' associated with severe viral infection ([@bib40]; [@bib73]; [@bib97]). Furthermore, sustained IFN production can cause alterations to the epigenetic landscape through chromatin remodelling, altering the scale of inflammatory responses resulting from immune stimulation ([@bib30]; [@bib56]). Effective regulation of cytokine production is therefore essential in the homeostasis between health and disease. Thus, our recent characterisation of ILRUN as an inhibitor of type-I IFNs and TNFα adds another component to this network, likely working in concert with other negative regulators of cytokine transcription, such as IL-37, sterile alpha motif and HD-domain-containing protein 1 (SAMHD1) and HLA-F adjacent transcript 10 (FAT10), which target various stages of the IFN induction pathway ([@bib3]; [@bib14]; [@bib20]; [@bib52]).

Unlike other cytokine inhibitors, however, ILRUN features an uncommon mechanism of action whereby IRF3-dependent transcription of these cytokines is blocked without impacting IRF3 activation, nuclear translocation or degradation ([@bib3]). Instead, ILRUN appears to carry out this function by inducing the degradation of the transcriptional co-activators CBP/p300, which participate in the transcription of the *IFNβ* gene as part of the IFNβ enhanceosome complex ([@bib3]). In the present study we demonstrate that the highly conserved UBA-like and NBR1-like domains of ILRUN are essential for its regulation of IFN production. To our knowledge, the only cellular protein comparable to ILRUN from a mechanistic perspective is cFLIPL (cellular FLICE-like inhibitory protein, long isoform), which shares no molecular homology with ILRUN but binds IRF3 to inhibit interactions between the transcriptional coactivator CBP and the IFN-β promoter ([@bib21]). Interestingly, cFLIPL also inhibits IRF7-dependent IFNα transcription by binding IκB kinase-α (IKKα) and preventing IKKα from phosphorylating and activating IRF7 ([@bib22]). The effect of ILRUN on steady-state CBP/p300 protein levels raises the possibility that, similar to cFLIPL, ILRUN regulates IFN signalling more broadly than only via IRF3.

Our expression analysis of ILRUN transcript expression in different human tissues revealed the highest abundance of ILRUNa in testis, heart, ovary and adipose. Small nucleotide polymorphisms (SNPs) in the *ILRUN* gene have been associated with increased risk of obesity ([@bib2]; [@bib5]; [@bib61]), therefore high levels of ILRUN in adipose may not be surprising. Expression in the testis and ovary may relate to the unique innate immune environment of these organs due to the need to avoid autoimmunity against gametes, preventing chronic inflammation that can lead to infertility and, in the case of the female reproductive tract (FRT), ensure tolerance to semen and the fetus ([@bib17]; [@bib46]). The FRT also constitutively expresses IFNε, a type-I IFN whose expression is highly restricted to the muscosal epithelium of the gut, lung, brain and FRT ([@bib17]). Strong expression of IFNε transcripts have also been detected in the testes of mice compared to other tissues ([@bib24]). Thus, ILRUN may have integral roles in maintaining immune homeostasis of reproductive organs. Furthermore, male germ cells are enriched in mRNA transcripts that undergo distinct spicing events to somatic cells, including truncation of 3′ UTRs ([@bib7]; [@bib44]; [@bib88]), consistent with the highest expression of the ILRUNc transcript, which lacks most of the 3' UTR present in ILRUNa and ILRUNb, occurring in testis. This may allude to potential functions of this isoform, and perhaps full-length ILRUN as well, in spermatogenesis if it is, in fact, translated into protein. Finally, aberrant IFN/IRF3 signalling is particularly detrimental to the heart, likely requiring strong inhibitory mechanisms to prevent tissue damage ([@bib31]), which may be mediated by ILRUN.

This analysis also showed an apparent abundance of ILRUNa transcripts in activated B-cells, CD4+ T-cells and macrophages. Prolonged type-I IFN signalling is detrimental to B- and T-cell function, leading to suppression of CD4+ T-cell function and generation of autoantibodies by B-cells ([@bib11]; [@bib38]; [@bib51]; [@bib54]; [@bib70]; [@bib96]). Thus, ILRUN may serve to temper IFN production by these cell types to prevent immune dysregulation. Dendritic cells, especially plasmacytoid dendritic cells, are professional type-I IFN producers ([@bib77]), therefore high levels of ILRUN may be necessary for shutting down the strong expression of type-I IFNs during infection by these cells following pathogen clearance.

Our investigation of the contributions of the domains of ILRUN to its ability to inhibit IRF3 signalling determined that both the UBA-like and NBR1-like domains are important. UBA-like domains are largely involved in binding to ubiquitin and targeting ubiquitinated proteins to the proteosome for degradation ([@bib64]); this would appear to be the likely function of this domain in ILRUN, enabling association to ubiquitinated CBP/p300 and promoting its degradation. However, both ubiquitin and UBA-like domains have additional diverse functions. Ubiquitin is also involved in DNA damage responses, cell cycle regulation, protein trafficking, signal transduction and protein scaffolding, dependent on the number and chain configuration of the ubiquitin tag ([@bib76]). UBA-like domains also mediate association with ULPs that are structurally similar to ubiquitin and are involved in various cellular process ([@bib84]). In relation to ILRUN, two ULPs of note are small ubiquitin-related modifier (SUMO), which has roles in gene transcription, and IFN-stimulated gene 15 (ISG15), which has antiviral functions ([@bib84]). Thus, the UBA-like domain of ILRUN has the potential to be multifunctional, enabling modulation multiple cellular processes.

FW/NBR1-like domains have been previously proposed to mediate homo- or heterodimerisation and/or associate with small molecules ([@bib1]). While the function of the FW domain of NBR1 still remains to be completely elucidated, studies have shown that this region interacts with the light chain of MAP1B, potentially to enable association with the microtubule cytoskeleton, a cellular structure with integral roles in autophagy ([@bib1]), suggesting that the ILRUN NBR1-like domain could be involved in mediating protein-protein interactions. Furthermore, truncations encompassing this domain in NBR1 contribute to its localisation to late endosomes and its ability to inhibit ligand-mediated receptor tyrosine kinase degradation ([@bib42]).

The C-terminal region of ILRUN is predicted to be largely disordered ([@bib1]), and our data suggests it does not contribute to antagonism of IRF3 signalling. However, intrinsically disordered regions (IDRs), regions of proteins that lack stable tertiary structure under physiological conditions, can provide great diversity to protein function by providing a means to potentially adopt multiple conformations in a regulated manner, enabling a single protein to effect diverse outcomes dependent on interactions with different ligands/proteins ([@bib81]; [@bib93]). IDRs are also regulated by post-translational modifications ([@bib4]), suggesting that the three phosphorylation sites identified in the disordered region of ILRUN may regulate its conformation/function. Thus, the lack of conservation of these sites in different species may indicate different modes of regulation. While the functions of IDRs are broad, RNA-binding proteins and transcriptions factors in particular are enriched for IDRs, indicating importance in regulating gene expression ([@bib6]; [@bib68]).

Whilst our work implicates ILRUN in antiviral immunity, other studies point to broader biological roles (summarised briefly in Supplementary Table A5). The role of ILRUN in inflammatory signalling, described by our group, in addition to unpublished findings relating to lipid metabolism ([@bib8]), form the basis for the name ILRUN. Roles in lipid metabolism may be associated with genome-wide SNP studies implicating ILRUN in obesity ([@bib2]; [@bib36]; [@bib41]; [@bib61]). These studies additionally suggest roles for ILRUN in height, the timing of pubescent growth spurts and coronary heart disease ([@bib36]; [@bib37]; [@bib72]; [@bib100]). In the context of cancer, increased expression of ILRUN mRNA and protein have been described in pancreatic, breast and non-small cell lung cancer (NSCLC) tissue, where expression positively correlates with poor NSCLC prognosis ([@bib28]; [@bib39]; [@bib99]). In pancreatic cancer tissue, overexpression of ILRUN increases cell proliferation and cancer cell invasion, possibly through stimulation of the ERK-P90RSK signalling pathway ([@bib39]). Additionally, due to the anti-cancer functions of type-I IFNs and TNFα ([@bib66]; [@bib102]), inhibition of these cytokines by ILRUN would likely also contribute to these apparent oncogenic effects.

An interesting hypothesis for future research is that, in addition to its regulation of type-I IFN and TNFα expression, ILRUN is linked to these diseases via its effect on the transcriptional coactivator proteins CBP/p300. We have shown that ILRUN reduces nuclear levels of CBP/p300 without impacting their expression in the cytoplasm ([@bib3]). These proteins are histone acetyltransferase (HAT) enzymes that catalyse the acetylation of lysine residues within promoter-bound histones, resulting in chromatin relaxation and modulation of transcription ([@bib12]). CBP/p300 interact with over 300 different cellular and viral binding partners to regulate physiological events including proliferation, differentiation, infection and apoptosis, among others ([@bib12]). Dysregulation of epigenetic modifications is associated with the pathology of many diseases, including coronary artery disease and cancer ([@bib26]; [@bib89]). Indeed, the domain composition of ILRUN could certainly suggest specific functions in transcription regulation, beyond simply acting as a 'chaperone' for CBP/p300 degradation. Together, the data presented here and the nominal literature available for ILRUN suggest it may have many functions/modes of action that impact on a number of cellular processes relevant to disease.

5. Conclusions {#sec5}
==============

In summary, ILRUN is a highly conserved regulator proinflammatory and antiviral cytokines, with its UBA-like and NBR1-like domains essential for this function. Expression of ILRUN transcripts is observed in all tissues and immune cell types examined and appears most highly expressed in testis and activated B-cells. Further work will be required to understand the mechanism by which ILRUN regulates inflammation and antiviral responses through its effects on CBP/p300 expression and to explore other potential biological functions for this protein.
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